Leerink Partnrs Weighs in on DexCom, Inc.’s FY2028 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Partnrs issued their FY2028 earnings estimates for DexCom in a research report issued on Thursday, March 28th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will post earnings of $3.97 per share for the year. The consensus estimate for DexCom’s current full-year earnings is $1.76 per share.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the firm posted $0.34 earnings per share. The firm’s revenue was up 26.9% on a year-over-year basis.

Several other analysts also recently commented on DXCM. Piper Sandler boosted their target price on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Wells Fargo & Company boosted their target price on shares of DexCom from $110.00 to $136.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 13th. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Morgan Stanley boosted their price objective on shares of DexCom from $101.00 to $122.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $136.67.

DexCom Stock Performance

DXCM stock opened at $138.70 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $53.47 billion, a price-to-earnings ratio of 105.88, a P/E/G ratio of 2.40 and a beta of 1.18. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00. The firm has a 50 day moving average of $125.54 and a two-hundred day moving average of $112.03.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,137 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now directly owns 76,304 shares in the company, valued at approximately $10,682,560. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Sadie Stern sold 4,137 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now directly owns 76,304 shares in the company, valued at approximately $10,682,560. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders sold a total of 183,635 shares of company stock worth $24,020,621 in the last ninety days. 0.41% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DexCom

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in DexCom by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 44,467,463 shares of the medical device company’s stock valued at $5,517,967,000 after buying an additional 278,458 shares during the period. Capital Research Global Investors increased its holdings in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after buying an additional 2,695,296 shares during the period. Sands Capital Management LLC increased its holdings in DexCom by 10.2% in the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after buying an additional 1,398,136 shares during the period. Capital World Investors increased its holdings in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after buying an additional 5,256,092 shares during the period. Finally, Geode Capital Management LLC increased its holdings in DexCom by 2.1% in the 1st quarter. Geode Capital Management LLC now owns 8,282,663 shares of the medical device company’s stock valued at $960,174,000 after buying an additional 170,796 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.